Daniel Piskorz

677 total citations
41 papers, 223 citations indexed

About

Daniel Piskorz is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, Daniel Piskorz has authored 41 papers receiving a total of 223 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Cardiology and Cardiovascular Medicine, 6 papers in Endocrinology, Diabetes and Metabolism and 5 papers in Economics and Econometrics. Recurrent topics in Daniel Piskorz's work include Blood Pressure and Hypertension Studies (18 papers), Cardiovascular Function and Risk Factors (11 papers) and Cardiac Health and Mental Health (5 papers). Daniel Piskorz is often cited by papers focused on Blood Pressure and Hypertension Studies (18 papers), Cardiovascular Function and Risk Factors (11 papers) and Cardiac Health and Mental Health (5 papers). Daniel Piskorz collaborates with scholars based in Argentina, Canada and Mexico. Daniel Piskorz's co-authors include Palmira Pramparo, Hermán Schargrodsky, Saúl Soifer, Eva Negri, Carlo La Vecchia, Adrián Baranchuk, Ricardo López Santi, Fernando Wyss, Álvaro Sosa Liprandi and Bryce Alexander and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and The American Journal of Cardiology.

In The Last Decade

Daniel Piskorz

34 papers receiving 211 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Piskorz Argentina 7 134 34 30 27 25 41 223
Patrice Zabsonré Burkina Faso 9 168 1.3× 63 1.9× 43 1.4× 20 0.7× 57 2.3× 77 272
Quang Ngoc Nguyen Vietnam 9 139 1.0× 32 0.9× 32 1.1× 10 0.4× 27 1.1× 28 261
Guiyuan Han China 6 74 0.6× 38 1.1× 30 1.0× 30 1.1× 64 2.6× 11 249
Masoud Malekzadeh Iran 8 124 0.9× 44 1.3× 36 1.2× 23 0.9× 52 2.1× 18 285
Eglé Silva Venezuela 6 107 0.8× 93 2.7× 29 1.0× 15 0.6× 39 1.6× 15 256
Priyanka Satish United States 9 126 0.9× 68 2.0× 60 2.0× 9 0.3× 43 1.7× 33 295
Pouria Alipour Canada 10 178 1.3× 28 0.8× 17 0.6× 13 0.5× 22 0.9× 29 303
Sally S. Wong United States 9 143 1.1× 29 0.9× 33 1.1× 10 0.4× 17 0.7× 13 290
K. Vijayakumar India 8 63 0.5× 36 1.1× 37 1.2× 6 0.2× 31 1.2× 21 198
Vidya Venugopal United States 8 55 0.4× 29 0.9× 16 0.5× 19 0.7× 25 1.0× 10 174

Countries citing papers authored by Daniel Piskorz

Since Specialization
Citations

This map shows the geographic impact of Daniel Piskorz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Piskorz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Piskorz more than expected).

Fields of papers citing papers by Daniel Piskorz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Piskorz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Piskorz. The network helps show where Daniel Piskorz may publish in the future.

Co-authorship network of co-authors of Daniel Piskorz

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Piskorz. A scholar is included among the top collaborators of Daniel Piskorz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Piskorz. Daniel Piskorz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brown, Jenifer M., et al.. (2026). New drug therapies for hypertension. The Lancet. 407(10532). 1014–1028.
2.
Alcocer, Luis, Ernesto L. Schiffrin, Gregory D. Fink, et al.. (2025). Racial and Gender Discrimination When Tailoring Medical Management to Hypertension Treatment in Latin America. American Journal of Hypertension. 38(10). 739–747.
3.
Molina, Dora I., António Coca, Luis Alcocer, & Daniel Piskorz. (2024). The Rationale for Using Fixed-Dose Combination Therapy in the Management of Hypertension in Colombia: A Narrative Review. American Journal of Cardiovascular Drugs. 24(2). 197–209. 1 indexed citations
4.
Piskorz, Daniel, et al.. (2024). Metabolic biomarkers and cardiovascular risk stratification in hypertension. Hipertensión y Riesgo Vascular. 41(3). 162–169.
5.
García-Zamora, Sebastián, Juan Farina, Laura Pulido, et al.. (2023). Violence and aggression against nurses during the COVID ‐19 pandemic in Latin America. From the emerging leaders program of the Interamerican Society of Cardiology ( SIAC ). Journal of Advanced Nursing. 80(3). 1212–1221. 1 indexed citations
6.
Santi, Ricardo López, Daniel Piskorz, Sebastián García-Zamora, et al.. (2022). The Attitudes of Physicians Toward Guideline Recommendations for the Management of Dyslipidemia in Clinical Practice - The VIPFARMA ISCP Project. Current Problems in Cardiology. 48(1). 101434–101434. 1 indexed citations
7.
Piskorz, Daniel, et al.. (2022). Diastolic dysfunction, hypertrophy and hypertension ventricular-arterial uncoupling treatment. Hypertension Research. 46(1). 136–143.
8.
Piskorz, Daniel, et al.. (2022). Ventricular-Arterial Uncoupling and Hypertension Mediated Diastolic Dysfunction. High Blood Pressure & Cardiovascular Prevention. 29(4). 361–366. 2 indexed citations
9.
Santi, Ricardo López, Felipe A. Martínez, Adrián Baranchuk, et al.. (2021). Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project. European Cardiology Review. 16. e16–e16. 1 indexed citations
10.
Liprandi, Álvaro Sosa, María Inés Sosa Liprandi, Ezequiel Zaidel, et al.. (2021). Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus document of the Inter-American Society of Cardiology and the Word Heart Federation. Global Heart. 16(1). 55–55. 11 indexed citations
11.
Piskorz, Daniel, et al.. (2021). Medium to Long Term Follow-Up of Treated Hypertensive Mediated Heart Disease. High Blood Pressure & Cardiovascular Prevention. 28(4). 383–391. 2 indexed citations
12.
Renna, Nicolás, Daniel Piskorz, Walter G. Espeche, et al.. (2021). Position statement on use of pharmacological combinations in a single pill for treatment of hypertension by Argentine Federation of Cardiology (FAC) and Argentine Society of Hypertension (SAHA). Journal of Human Hypertension. 37(6). 438–448. 1 indexed citations
13.
Piskorz, Daniel, et al.. (2020). Psychological Impact of the Pandemic on Ambulatory Cardiometabolic Patients Without Evidence of SARS-CoV-2 Infection. The CorCOVID Latam Psy Study. Current Problems in Cardiology. 46(4). 100737–100737. 9 indexed citations
14.
Piskorz, Daniel. (2020). Hypertensive Mediated Organ Damage and Hypertension Management. How to Assess Beneficial Effects of Antihypertensive Treatments?. High Blood Pressure & Cardiovascular Prevention. 27(1). 9–17. 30 indexed citations
15.
Santi, Ricardo López, Sohaib Haseeb, Bryce Alexander, et al.. (2018). Attitudes and Recommendations of Physicians towards Alcohol Consumption and Cardiovascular Health: A Perspective from Argentina. SHILAP Revista de lepidopterología. 6(3). 77–77. 7 indexed citations
16.
Piskorz, Daniel, et al.. (2011). La disfunción diastólica en pacientes hipertensos no es debida a hipertrofia ventricular izquierda. Redalyc (Universidad Autónoma del Estado de México). 6(1). 2–7. 3 indexed citations
17.
Sierra, Alejandro de la, et al.. (2009). Diferencias en el impacto de los componentes del síndrome metabólico entre la población hipertensa latinoamericana y la española. Medicina Clínica. 133(2). 47–52. 4 indexed citations
18.
Piskorz, Daniel, et al.. (2009). Descenso espontáneo de la frecuencia cardíaca y regresión de la hipertrofia ventricular izquierda. Redalyc (Universidad Autónoma del Estado de México). 4(1). 44–49.
19.
Piskorz, Daniel, et al.. (2007). Obesidad central y regresión de hipertrofia ventricular izquierda. Redalyc (Universidad Autónoma del Estado de México). 2(4). 159–162. 2 indexed citations
20.
Schargrodsky, Hermán, Palmira Pramparo, Daniel Piskorz, et al.. (1997). Frequency of Family History of Acute Myocardial Infarction in Patients With Acute Myocardial Infarction. The American Journal of Cardiology. 80(2). 122–127. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrice Zabsonré Breakdown of academic impact, for papers by Quang Ngoc Nguyen Breakdown of academic impact, for papers by Guiyuan Han Breakdown of academic impact, for papers by Masoud Malekzadeh Breakdown of academic impact, for papers by Eglé Silva Breakdown of academic impact, for papers by Priyanka Satish Breakdown of academic impact, for papers by Pouria Alipour Breakdown of academic impact, for papers by Sally S. Wong Breakdown of academic impact, for papers by K. Vijayakumar Breakdown of academic impact, for papers by Vidya Venugopal
Rankless by CCL
2026